Mark Eutsler’s Post

#ewimed Report 2024: IPC during ongoing chemotherapy 🩺💉 Many patients develop #pleural effusion or #ascites in the course of their oncological disease. This leads often to uncertainty as to whether and when an IPC should be implanted. This chapter disproves these uncertainties and illustrates that an IPC can be implanted during ongoing chemotherapy. Dive into our literature review and our medical interview with the oncologist Dr Yannick Buccella, who talks about his experiences with IPC during chemotherapy. This and other interesting topics can be found in our ewimed Report 2024! Download for free: https://lnkd.in/e6PtSAA7 #ewimed #ewimedswitzerland #medicaltechnology #report #catheter #drainage #palliative #pleural effusion #ascites #chemotherapy

Diversity in clinical trials - have you given any thoughts about your diversity plans? How exactly can you execute these plans? More importantly... where to even start? Fortrea offers a comprehensive and integrated "5-part process" solution for establishing, monitoring and reporting on Diversity Plan metrics in a clinical trials. Curious? Drop me a message! Or take a look at Joshua Richter's article - discusses the lack of diversity in clinical trials and how community oncologists can help overcome these disparities. #DiversityPlan #ClinicalTrials #oncology #diversity #Phase3

We are delighted to announce one of the biggest milestones in our mission to transform chronic wound care — our CLEANVLU Phase IIa clinical trial report, which demonstrates proof-of-concept and safety of Aurase Wound Gel in humans, has now been published in International Wound Journal. Aurase Wound Gel aims to provide, for the first time, a safe, pain-free, and effective treatment for millions of people suffering from chronic wounds worldwide, and we are incredibly excited to be progressing this product through further Phase II studies. Our Chairman of the Board, Andy Weymann, MD, MBA, comments: “The peer-review publication of our Phase IIa data not only provides important validation to enable further Phase II studies, but also highlights the clinical potential of Aurase Wound Gel to treat millions of patients globally safely and effectively, addressing an urgent and unmet medical need. With this excellent data we are now fundraising to support the next phase of SolasCure’s clinical and product development.” Learn more here: https://lnkd.in/d4EbWtYd #WoundCare #ChronicWounds #ClinicalTrials #HealthCare

⏳ The countdown begins! Just 2 weeks until our must-attend webinar harnessing STING & TLR. 🔗 Register Now: https://ter.li/z3x8at Get ready to explore the latest clinical trials, uncover promising combination treatments, and gain insights into the innovative strategies that are revolutionizing STING & TLR-targeted therapies. Don’t miss out! #ImmunoOncology #STING #TLR #Checkpoint

This webinar will explore innovative approaches to accelerate clinical trials using big data strategies and AI. #drugdevelopment #clinicaltrials #oncology

With major advances in the understanding of cancer, the cancer treatment landscape has evolved, resulting in significant changes in therapy and in turn the primary endpoints elected for cancer clinical trials. Experts emphasize the need for transparency when changing primary endpoints in oncology clinical trials.

Incredible results in a challenging study proves #Dermtech can accurately rule out melanoma greater than 99% of the time. Trust II is a follow up study on an already successful trial; which is rarely done. The reason being that the possibility of contradicting your initial positive results is a risk very few companies are willing to take. #Dermtech enrolled 8,000 more patients than Trust I to validate its claims as a first in class melanoma rule out test. The outcome provides concordance to TRUST 1 that the NPV for this test is still greater than 99%

We celebrate Clinical Trials Day on May 20, marking the start of the first randomized clinical trial by James Lind in 1747. Since then, clinical trials have evolved significantly. Today, they are essential in developing treatments for conditions like myeloma. We thank everyone involved in myeloma clinical trials, from researchers to participants, for their crucial role in advancing safe and effective treatments. #ClinicalTrialsDay #canadianmyelomaresearchgroup #MedicalAdvancements #ResearchHeroes #DrugDevelopment #HealthcareInnovation #PatientAdvocacy #ScienceProgress #ClinicalResearch

Explore the groundbreaking results from the ENSEMBLE Phase IIIb study on Ocrelizumab (OCR) for early-stage Relapsing-Remitting Multiple Sclerosis (RRMS). Sponsored by Hoffmann-La Roche, this study showcases the efficacy and safety of the groundbreaking medication in treatment-naive patients. #MultipleScrelosis #MS #Research #Ocrelizumab #ClinicalTrials 

During #CART24, Steve Kalloger, MSc, Head of Research at LC, spoke with Healio | HemOnc Today about the experience of patients who have received CAR-T therapy. This study reveals that the mosaic of side effects experienced by those receiving CAR-T may extend beyond what is typically reported. You can read the rest of the article at: https://lnkd.in/gkkrT5Vz #lymsm